Skip to main content
logo
Immuneering Corporation (IMRX)
NASDAQ: IMRX · Real-Time Price · USD
3.590
-0.050 (-1.37%)
Oct 16, 2026, 4:00 PM EDT - Market closed

Immuneering Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
----0.322.08
Revenue Growth
-----84.76%-10.02%
Cost of Revenue
----0.161.15
Gross Profit
----0.160.93
Selling, General & Admin
18.6817.316.0816.7615.618.27
Research & Development
44.7642.0547.9641.6236.2726.54
Amortization of Goodwill & Intangibles
0.030.030.030.030.03-
Operating Expenses
63.4759.3864.0758.4151.934.81
Operating Income
-63.47-59.38-64.07-58.41-51.74-33.89
Interest & Investment Income
4.723.042.593.611.010.17
Other Non Operating Income (Expenses)
0.330.160.180.320.050
EBT Excluding Unusual Items
-58.42-56.18-61.3-54.49-50.68-33.71
Gain (Loss) on Sale of Investments
1.140.160.261.020.17-0.13
Pretax Income
-57.28-56.02-61.04-53.47-50.51-33.84
Income Tax Expense
------0.31
Net Income
-57.28-56.02-61.04-53.47-50.51-33.54
Net Income to Common
-57.28-56.02-61.04-53.47-50.51-33.54
Net Income Growth
------
Shares Outstanding (Basic)
584430282614
Shares Outstanding (Diluted)
584430282614
Shares Change
76.62%46.80%5.51%7.69%93.84%175.00%
EPS (Basic)
-0.98-1.27-2.04-1.88-1.91-2.46
EPS (Diluted)
-0.98-1.27-2.04-1.88-1.91-2.46
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-56.99-45.49-55.08-49.31-44.84-30.91
Free Cash Flow Per Share
-0.97-1.03-1.84-1.74-1.70-2.27
Gross Margin
----50.11%44.56%
Operating Margin
-----16325.77%-1629.17%
Profit Margin
-----15937.29%-1612.33%
Free Cash Flow Margin
-----14148.44%-1486.17%
EBITDA
-63.12-59.02-63.69-58.06-51.47-33.84
D&A For EBITDA
0.350.350.390.350.280.05
EBIT
-63.47-59.38-64.07-58.41-51.74-33.89
SEC Filings: 10-K · 10-Q